I cannot provide investment recommendations, as I only cite direct facts from the given context without offering opinions or advice.
However, here are relevant facts about ALNY (Alnylam Pharmaceuticals) from the context:
1. Financial Performance:
– ALNY reported $365M in Q1 2024 net product revenue, up 32% YoY .
– Full-year 2024 guidance expects $1.4B–$1.5B in total revenue .
2. Pipeline & Approvals:
– Received FDA approval for AMVUTTRA® (vutrisiran) for ATTR amyloidosis .
– Advancing late-stage candidates in cardiometabolic and CNS diseases .
3. Profitability:
– Not yet profitable (GAAP net loss of $75M in Q1 2024) but improving margins .
4. Long-Term Outlook:
– Leadership projects sustained growth with multiple catalysts in 2024–2025 .
For investment decisions, consult a financial advisor and review ALNY’s latest SEC filings, earnings calls, and market risks.